Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051699 | 0.75 | NPY1R (0.48) | — | |
| SCHEMBL1082776 | 0.69 | HTR4 (0.40) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11811721 | 0.68 | APEX1 (0.50) | — | |
| SCHEMBL11376454 | 0.67 | TSHR (0.45) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27677248 | 0.66 | SLC6A2 (0.45) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8147504 | 0.66 | TSHR (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL6955745 | 0.65 | CYP1A2 (0.59) | — | |
| Hydrochloric Acid SCHEMBL7478017 | 0.65 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8684650 | 0.64 | ALDH1A1 (0.47) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27677257 | 0.62 | SLC6A2 (0.40) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322622-B1 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | SPROUT PHARMACEUTICALS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1322622-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6521623-B1 | 1-(2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl)-3-(2-hydroxyethyl) -1,3-dihydro-2H-benzimidazol-2-one for example; treating anxiety disorders and psychological disorders, brain injuries | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | Salix Pharmaceuticals, Ltd | 2003-02-06 | — | — | US | disclosed |
| WO-2002024661-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR3C | SLC6A3 28/4885SLC6A2 79/4885SLC6A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.